Article Text

  1. A Braguglia1,
  2. A Conforti1,
  3. N Chukhlantseva1,
  4. F Morini1,
  5. A Dotta1,
  6. R Masi2,
  7. S M Orlando1,
  8. P Bagolan1,
  9. C Corchia1
  1. 1Department of Medical and Surgical Neonatology, Bambino Gesu Children’s Hospital, Rome, Italy
  2. 2Unit of Otorhinolaryngology, Bambino Gesu Children’s Hospital, Rome, Italy


Aim New treatments have improved survival rate in CDH infants in comparison with past decades. However this better survival has raised concern about the long term morbidity, particularly in the first few years of life. Aim of our study is to evaluate the role of a multidisciplinary follow up for high risk CDH survivors.

Methods All high risk CDH survivors consecutively treated between 2004 and 2007 were included into our follow-up clinics. Prevalence of late morbidity was prospectively evaluated at 6 months, 1 and 2 years. Clinical examinations included auxological, gastro-intestinal, pulmonary, orthopedic and audiological evaluation. Comparison of prevalences at various ages was performed with the McNemar test.

Results 44 patients were enrolled into our follow-up program. Main results are summarized in the table.

Braguglia et al

Conclusion CDH survivors may present late morbidity. Our results highlight the importance of a multidisciplinary long term follow up to limit sequelae. Particularly, oral aversion and orthopedic disorders significantly increase with the age in our series, recommending a long term evaluation. More studies are needed to better understand the role of new treatments in the development of late morbidity in CDH survivors.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.